8 patents currently held
44 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Nov 2033. from the record
Of the 44 now held by other companies, 38 name BioNTech SE as their current owner, and 6 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Nov 2033
Next term end
6
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jul 2038 · High confidence
Also notable
Ends Dec 2033 · High confidence
Also notable
Ends Nov 2033 · High confidence
Methods and Compositions for Stimulating Immune Response
US 11,471,522
The most cited patent in this portfolio, cited by 7 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
T Cell Receptors with MHC Independent Binding to Gm-Csf Receptor Alpha Chain
US 9,861,688
Granted 2018 and renewed at every maintenance window due so far. Protection runs to 2033.
Individualized Vaccines for Cancer
US 12,642,844
Granted 2026. Too new for citation comparison; protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Formerly held, still cited
Notable
Ends May 2032 · High confidence
The most cited patent in this portfolio, cited by 205 later US patents, top 1% of utility patents granted in 2020 in our data. Protection runs to 2032.
now held by BioNTech SE
Also notable
Ends Apr 2036 · High confidence
Cited by 21 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2036.
now held by BioNTech SE
Also notable
Ends Mar 2032 · High confidence
Cited by 23 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2032.
now held by BioNTech SE
Fee deadlines
No maintenance fee falls due on this company's record before Nov 17, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The 5 largest of its 6 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Methods and Compositions for Stimulating Immune Response | 2 in force | to Jul 2038 |
| T Cell Receptors with MHC Independent Binding to Gm-Csf Receptor Alpha Chain | 2 in force | to Dec 2033 |
| RNA Particles Comprising Polysarcosine | 1 in force | to Jan 2042 |
| 5'-CAP-TRINUCLEOTIDE- or Higher Oligonucleotide Compounds and Their Use in Stabilizing RNA, Expressing Proteins in Therapy | 1 in force | to May 2041 |
| Stable Formulations of Lipids and Liposomes | 1 in force | to Sep 2035 |
Patents held now
Soonest term end first.
Showing 1 to 8 of 8
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 12,642,844 | Individualized Vaccines for Cancer In force · High confidence | In force | High confidence | |
| US 9,861,688 | T Cell Receptors with MHC Independent Binding to Gm-Csf Receptor Alpha Chain In force · High confidence | In force | High confidence | |
| US 10,987,413 | Novel MHC-Independent Tumor-Associated Antigens In force · High confidence | In force | High confidence | |
| US 12,220,484 | Stable Formulations of Lipids and Liposomes held by BioNTech SE In force · Low confidence | In force | Low confidence | |
| US 12,168,051 | Methods and Compositions for Stimulating Immune Response In force · High confidence | In force | High confidence | |
| US 11,471,522 | Methods and Compositions for Stimulating Immune Response In force · High confidence | In force | High confidence | |
| US 12,281,138 | 5'-CAP-TRINUCLEOTIDE- or Higher Oligonucleotide Compounds and Their Use in Stabilizing RNA, Expressing Proteins in Therapy held by BioNTech SE In force · High confidence | In force | High confidence | |
| US 12,419,965 | RNA Particles Comprising Polysarcosine In force · High confidence | In force | High confidence |
Also on record, not counted in the 8: 44 patents in force now held by others · 1 patent ended · 16 applications pending · 7 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.